Notice of Annual General Meeting 2026
Telix announces its Annual General Meeting of shareholders to be held...
Read moreLatest News
Category: ASX
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
Telix today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s pivotal IPAX BrIGHT trial, marking the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma,...
Read more
Telix and Regeneron Announce Strategic Radiopharma Collaboration
Telix and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN, “Regeneron”) today announce a collaboration to jointly develop and commercialize next generation radiopharmaceutical...
Read more
FDA Accepts NDA for TLX101-Px (Pixclara®)
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Company’s resubmitted New Drug Application (NDA) for TLX101-Px, (Pixclara®, Floretyrosine F 18 or 18F-FET), an...
Read more
Telix Strengthens Board with Additional Director Appointments
Telix today announces two additional Non-Executive Director (NED) appointments, effective May 11, 2026, as part of Board expansion and succession...
Read more
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
Telix provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1...
Read more
Telix Appoints David Gill as Non-Executive Director
Telix today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 2026. Mr. Gill...
Read more
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
Telix today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®, Floretyrosine F 18 or 18F-FET), an investigational...
Read more
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
Telix today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has...
Read more
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
Telix today announces its financial results for the year ended December 31,...
Read more